• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • Write for us
  • Contact us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home All Specialties Hematology

Vemurafenib plus rituximab associated with complete response in refractory hairy-cell leukemia

bySze Wah Samuel ChanandHarsh Shah
June 7, 2021
in Hematology, Oncology
Reading Time: 2 mins read
0
Share on FacebookShare on Twitter

1. Vemurafenib plus rituximab treatment was associated with complete response for refractory or relapsed hairy-cell leukemia patients.

2. Post hoc analysis suggested minimal residual disease negative status and the lack of prior v-raf murine sarcoma viral oncogene homolog B1 (BRAF) inhibitors exposure were associated with better survival.

Evidence Rating Level: 2 (Good)

Study Rundown: Hair-cell leukemia (HCL) is a B-cell neoplasm that is driven by the BRAF V600E activating mutation. BRAF V600E inhibitors have been shown, in previous studies, to be an encouraging treatment, but residual disease remained after monotherapy treatment. The resistant cancer cells still maintain their CD20 receptors, highlighting the potential for a dual blockade. As such, this study treated relapsed or refractory hairy-cell leukemia patients with a combination of vemurafenib, a BRAF inhibitor, and rituximab, and anti-CD20 monoclonal antibody. The study determined most patients had a complete response with no minimal residual disease after treatment. The adverse event profile was consistent with previous studies of monotherapies. The adverse events consisted of infusion reactions for rituximab along with photosensitivity, arthralgias, and cutaneous rashes for vemurafenib. The study was limited by the small sample size and lack of a comparator arm. Nonetheless, the study’s results are significant, as the trial demonstrated a short, chemotherapy-free, nonmyelotoxic regimen of vemurafenib plus rituximab was associated with a complete response in refractory or relapsed hairy-cell leukemia.

Click here to read the study in the NEJM

Relevant Reading: BRAF Mutations in Hairy-Cell Leukemia

In-Depth [prospective cohort]: The single-arm, single-center, phase 2 clinical trial enrolled 31 patients in Italy. The study inclusion criteria consisted of patients with refractory or relapsed HCL, mutated BRAF V600E, and previous treatment with a BRAF inhibitor. Patients without cytopenia were excluded from the study. All patients were treated with eight weeks of vemurafenib (960 mg, twice daily) and eight rituximab infusions (375 mg per square meter of body-surface area) over an 18 week period. The primary endpoint was a complete response at the end of planned treatment, which was assessed four weeks after the last rituximab dose. A complete response was defined as resolution of cytopenias, no palpable splenomegaly, and no hairy cells visible in bone marrow biopsy or blood smear samples. Minimal residual disease (MRD) was assessed by polymerase-chain-reaction (PCR) for BRAF V600E in bone-marrow and peripheral samples. At the end of the treatment period, 87% (26 out of 30) of patients had a complete response, out of which, 65% (17 out of 26) had minimal residual disease resolution. Progression-free survival from the intention-to-treat population was 78% at a median follow-up of 37 months. Drug-related adverse events included infusion-related reactions, transient neutropenia, rash, and photosensitivity. Post hoc analysis suggested that MRD negativity and no prior exposure to BRAF inhibitors correlated to improved survival. In general, the study found a vemurafenib plus rituximab treatment was associated with complete response in refractory or relapsed hairy-cell leukemia patients.

RELATED REPORTS

#StudyGraphics: Atezolizumab in combination with vemurafenib and cobimetinib improve progression-free survival in patients with BRAFV600-advanced melanoma

#VisualAbstract: Rituximab plus lenalidomide shows comparable survival compared to chemotherapy for CD20⁺ follicular lymphoma

Single dose of rituximab for new-onset myasthenia gravis associated with reduced risk of disease manifestations – The RINOMAX Randomized Clinical Trial

Image: PD

©2021 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

Tags: anti-CD20 monoclonal antibodyBRAF inhibitorhairy-cell leukemiarituximabVemurafenib
Previous Post

Randomized trial of plant-derived vaccine for COVID-19

Next Post

Tympanostomy tubes not superior to medical management for recurrent acute otitis media

RelatedReports

#StudyGraphics: Atezolizumab in combination with vemurafenib and cobimetinib improve progression-free survival in patients with BRAFV600-advanced melanoma
StudyGraphics

#StudyGraphics: Atezolizumab in combination with vemurafenib and cobimetinib improve progression-free survival in patients with BRAFV600-advanced melanoma

March 15, 2023
#VisualAbstract: Chemoradiotherapy with carboplatin is more effective than cetuximab in head and neck squamous cell carcinoma
StudyGraphics

#VisualAbstract: Rituximab plus lenalidomide shows comparable survival compared to chemotherapy for CD20⁺ follicular lymphoma

October 19, 2022
Autologous hematopoietic stem cell transplantation associated with long-term remission in myasthenia gravis
Chronic Disease

Single dose of rituximab for new-onset myasthenia gravis associated with reduced risk of disease manifestations – The RINOMAX Randomized Clinical Trial

September 28, 2022
#VisualAbstract: Adding four doses of rituximab did not significantly improve event-free survival over standard of care in acute lymphoblastic leukaemia
StudyGraphics

#VisualAbstract: Adding four doses of rituximab did not significantly improve event-free survival over standard of care in acute lymphoblastic leukaemia

April 8, 2022
Next Post
Patient Basics: Middle-Ear Infection (Otitis Media)

Tympanostomy tubes not superior to medical management for recurrent acute otitis media

2 Minute Medicine Rewind October 14, 2019

Net fluid balance not associated with hospital readmission rates among sepsis patients

Rilonacept may lower pericarditis recurrence in patients with relapsing pericarditis

Carriers of genetic variants of inherited cardiomyopathies and arrhythmias associated with unexplained sudden cardiac death

License Our Award-Winning Physician-Written Medical News and Visual Abstracts

2 Minute Medicine is the leading authoritative medical news licensing service, and the only with reports written by practicing doctors.

LICENSE CONTENT

2MM+ Premium Access

No ads & unlimited access to all current reports, over 9000 searchable archived reports, visual abstracts, Weekly Rewinds, and the online edition of The Classics Series™ textbook.

Subscription Options
2 Minute Medicine

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Transcarotid artery revascularization not associated with a significant difference in 30-day risk of stroke, death and myocardial infarction compared to carotid endarterectomy
  • Drinking characteristics in adolescence predict alcohol behaviors in early adulthood
  • Sodium-glucose co-transporter-2 inhibitors may decrease risk of in-stent thrombosis
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

Want more physician-written
medical news?

Join over 10 million yearly readers and numerous companies. For healthcare professionals
and the public.

Subscribe for free today!

Subscription options